June 28, 2016 –Celltex client Sarah Hughes, has been personally invited to the FDA Hearing on Draft Guidance’s Relating to the Regulation of HCT/PS, taking place September 12 – 13, 2016 at the National Institute of Health in Bethesda, MD. Hughes will address the FDA and share her personal stem cell therapy experience in front of hundreds of regulators, medical experts, researchers and stem cell advocates.
2014 – Before first transfusion, Sarah Hughes in Cancun before her first adult stem cell therapy .
Hughes, who was diagnosed with Systemic Juvenile Idiopathic Arthritis (SJIA) during her childhood, has spent most of her lifetime in and out of hospitals and in constant pain. Doctors predicted she would die prematurely in her early 20’s. After years of searching for options and experiencing no relief from conventional medicines, 22-year-old Hughes turned to Celltex for adult stem cell therapy. Eighteen months after receiving the first intravenous transfusion of her own adult mesenchymal stem cells (MSCs), Hughes has experienced a remarkable transformation. She has been able to reduce the number of prescription drugs that she takes every day from 23 to eight, is able to eat and absorb nutrients, and has not needed chemotherapy or been immune-suppressed since her first transfusion in November 2014. “Before stem cell therapy, I wasn’t planning my future because I didn’t have one. Now, I wake up every day and I am overwhelmed thinking about all the choices I have that I didn’t have before,” Hughes says. “I also think about the millions of people in this country who live with a chronic illness and who could benefit from adult stem cell therapy but are probably too sick to get on an airplane.”
2016 – 18 months after first transfusion, Sarah Hughes with her horse Stirling Bridge.
Nearly 117 million Americans are chronically ill according to the Center for Disease Control and Prevention. Seven of the top 10 causes of death in the United States are chronic diseases and arthritis is now the most common cause of disability in America. As of today, the FDA considers stem cells that are expanded in large numbers through cell culturing to be a drug, forcing many people to explore stem cell therapy options outside of the United States. Sarah is hopeful that after sharing her powerful journey and unbelievable progress, the FDA will take strides to make receiving adult stem cell therapy in the United States easier for the millions of Americans living in pain.
The post Celltex Client Sarah Hughes Invited to Speak at FDA Stem Cell Hearing in September appeared first on Celltex Therapeutics.